Chardan analyst Geulah Livshits lowered the firm’s price target on Metagenomi (MGX) to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi Announces Positive Preclinical Data for MGX-001
- Metagenomi CEO Brian Thomas to transition out of role, Jian Irish to succeed
- Metagenomi reports Q3 EPS (55c), consensus (53c)
- Metagenomi reports new dose range finding data from MGX-001 hemophilia A program
- Metagenomi reduces workforce by 25%